CB2 receptor agonist 6 (compound 70) is an agonist of CB2R, with EC50 of 162 nM. The IC50 values of CB2 receptor agonist 6 are 4.83 μM for CB1R and 0.88 μM for CB2R. CB2 receptor agonist 6 is a neuroprotective agent that can be used for the reseach of neurological disease[1].

CB2 receptor agonist 7 (Compound 5B) is a cannabinoid 2 (CB2) receptor agonist with blood-brain barrier permeability[1].

CB2 receptor antagonist 5 (compound 4A) is a ligand of CB2 receptor with antagonist effect[1].

CBARP Human Pre-designed siRNA Set A contains three designed siRNAs for CBARP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CBFA2T2 Human Pre-designed siRNA Set A contains three designed siRNAs for CBFA2T2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CBFA2T3 Human Pre-designed siRNA Set A contains three designed siRNAs for CBFA2T3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CBFB Human Pre-designed siRNA Set A contains three designed siRNAs for CBFB gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CBI1 is a covalent BAX inhibitor. CBI1 selectively derivatizes BAX at C126 and inhibits BAX activation by triggering ligands or point mutagenesis. CBI1 blocks t-2-hex lipidation and oligomerization of BAX. CBI1 inhibits BAX activation induced by BH3 ligands, F116A mutagenesis or t-2-hex[1].

CBL Human Pre-designed siRNA Set A contains three designed siRNAs for CBL gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cbl-b-IN-17 (Example-40) is an inhibitor of Cbl-b with an IC50 value

Cbl-b-IN-18 (compound 51) is an inhibitor of the E3 ligase Casitas B-lineage lymphoma proto-oncogene B (CPL-B). Cbl-b-IN-18 inhibits the phosphorylation of CPL-B (IC50< 100 nM)[1].

Cbl-b-IN-19 (Compound 49) is an inhibitor for casitas B-lineage lymphoma b(Cbl-b), that inhibits Cbl-b phosphorylation with an IC50 < 100 nM[1].

Cbl-b-IN-20 (Example 50) is a casitas proto-oncogene-B ( CPL-B ) inhibitor with IC50

CBLB Human Pre-designed siRNA Set A contains three designed siRNAs for CBLB gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CBLC Human Pre-designed siRNA Set A contains three designed siRNAs for CBLC gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CBLIF Human Pre-designed siRNA Set A contains three designed siRNAs for CBLIF gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CBLL1 Human Pre-designed siRNA Set A contains three designed siRNAs for CBLL1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CBLN1 Human Pre-designed siRNA Set A contains three designed siRNAs for CBLN1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CBLN2 Human Pre-designed siRNA Set A contains three designed siRNAs for CBLN2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CBLN4 Human Pre-designed siRNA Set A contains three designed siRNAs for CBLN4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CBP/p300 ligand 4 (Compound 4) is an orally active inhibitor for CBP/p300 bromodomain, with IC50 of 91.4 nM. CBP/p300 ligand 4 serves as a ligand for target protein XYD190 (HY-161495). XYD190 is a PROTAC degrader for CBP/p300[1].

CBPD-268 is a potent and orally active CBP/p300 PROTAC degrader with an DC50 value of ≤ 0.03 nM. CBPD-268 induces CBP/p300 degradation and inhibits cell growth. CBPD-268 shows antitumor activity. CBPD-268 has the potential for the research of AR-positive prostate cancer (Srtucture Note: Red, Androgen receptor degrader (HY-W248665A); Blue, CBP/p300 ligand (HY-161483); Black, Linker)[1].

CBPD-409 is an orally active PROTAC degrader for CBP/p300, with DC50 of 0.2–0.4 nM. CBPD-409 exhibits antiproliferative effects in AR+ prostate cancer cell lines VCaP, LNCaP and 22Rv1, with IC50s of 1.2–2.0 nM. CBPD-409 exhibits antitumor efficacy (Red: CBP inhibitor GNE049 (HY-108435); Blue: CRBN/cullin 4A Thalidomide (HY-14658); Black: Linker)[1].

CBR1 Human Pre-designed siRNA Set A contains three designed siRNAs for CBR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CBR3 Human Pre-designed siRNA Set A contains three designed siRNAs for CBR3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CBR4 Human Pre-designed siRNA Set A contains three designed siRNAs for CBR4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CBS Human Pre-designed siRNA Set A contains three designed siRNAs for CBS gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

cBu-Cit-OH (Mal-cyclobutane-1) is an ADC Linker that can be used to synthesize ADCs[1].

CBX1 Human Pre-designed siRNA Set A contains three designed siRNAs for CBX1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CBX2 Human Pre-designed siRNA Set A contains three designed siRNAs for CBX2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CBX3 Human Pre-designed siRNA Set A contains three designed siRNAs for CBX3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CBX4 Human Pre-designed siRNA Set A contains three designed siRNAs for CBX4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CBX5 Human Pre-designed siRNA Set A contains three designed siRNAs for CBX5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CBX6 Human Pre-designed siRNA Set A contains three designed siRNAs for CBX6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CBX7 Human Pre-designed siRNA Set A contains three designed siRNAs for CBX7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CBX8 Human Pre-designed siRNA Set A contains three designed siRNAs for CBX8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CBY1 Human Pre-designed siRNA Set A contains three designed siRNAs for CBY1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CBY2 Human Pre-designed siRNA Set A contains three designed siRNAs for CBY2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CbZ-Ala-Ala-Ala-Ala is a modified peptide[1].

Cbz-Gly-Pro-Ala-O-cinnamyl (compound 25) is a small peptide targeting BACE-1 and AChE with the IC50 values of 0.02 μM and 1 μM, respectively. Cbz-Gly-Pro-Ala-O-cinnamyl shows neuroprotective effect and can be used for study of Alzheimer’s disease[1].

CC-885-CH2-PEG1-NH-CH3 TFA is a new degrader that can be used to synthesize antibody-based novel degrader conjugated active molecules (AnDC)[1][2].

CC-885-CH2-PEG1-NH-CH3 TFA is a new degrader that can be used to synthesize antibody-based novel degrader conjugated active molecules (AnDC)[1][2].

CC-885-CH2-PEG1-NH-CH3 TFA is a new degrader that can be used to synthesize antibody-based novel degrader conjugated active molecules (AnDC)[1][2].